SCHEMBL5457877

SCHEMBL5457877

NC(=O)c1c(NC(=O)Nc2cc(Cl)cc(Cl)c2)sc2c1CCOC2

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 1/20 0.57
KCNH2 Q12809 9/20 0.54
PTPRC P08575 1/20 0.49
PTPN2 P17706 1/20 0.49
PTPN1 P18031 1/20 0.49
PTPRB P23467 1/20 0.49
PTPRE P23469 1/20 0.49
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
EPHB4 P54760 1/20 0.47
KDM4E B2RXH2 1/20 0.47
USP2 O75604 1/20 0.47
LMNA P02545 1/20 0.47
MAPT P10636 1/20 0.47
HTT P42858 1/20 0.47
ATM Q13315 1/20 0.47
ANO1 Q5XXA6 2/20 0.47
CNR2 P34972 4/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5467205 0.89 CFTR (0.56) CFTRKCNH2MEN1KMT2ANPC1
SCHEMBL16962264 0.89 KCNH2 (0.68) CFTRKCNH2PTPRCPTPN2PTPN1
SCHEMBL5454317 0.87 MEN1 (0.63) CFTRKCNH2PTPRCPTPN2PTPN1
SCHEMBL5450945 0.86 CFTR (0.54) CFTRKCNH2PTPRCPTPN2PTPN1
SCHEMBL5453060 0.85 CFTR (0.54) CFTRKCNH2MEN1KMT2ANPC1
SCHEMBL5455947 0.85 MEN1 (0.65) CFTRKCNH2PTPRCPTPN2PTPN1
SCHEMBL5465615 0.84 KCNH2 (0.53) CFTRKCNH2PTPRCPTPN2PTPN1
SCHEMBL5450806 0.84 CFTR (0.57) CFTRKCNH2PTPRCPTPN2PTPN1
SCHEMBL5460654 0.84 ANO1 (0.64) CFTRKCNH2PTPRCPTPN2PTPN1
SCHEMBL5455531 0.83 FLT3 (0.61) CFTRKCNH2MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 CFTR 2030/4885KCNH2 3409/4885PTPRC 1457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.